Newborn screening for cystic fibrosis

Current Opinion in Pediatrics

Volumn 24, Issue 3, 2012, Pages 329-335

  Wagener, Jeffrey S ^a   Zemanick, Edith T ^a   Sontag, Marci K ^b  

^a UNIVERSITY OF COLORADO   (United States)

^b Department of Civil and Environmental Engineering at Colorado State University and the Department of Environmental and Occupational Health at the Colorado School of Public Health   (United States)

Author keywords

CFTR related metabolic syndrome; cystic fibrosis; immunoreactive trypsinogen; mutation analysis; newborn screening

Indexed keywords

ANTIBIOTIC AGENT; PANCREATITIS ASSOCIATED PROTEIN; TRYPSINOGEN;

ANTIBIOTIC THERAPY; BREAST FEEDING; BRONCHOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; EARLY DIAGNOSIS; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE MUTATION; GENETIC COUNSELING; GENETIC VARIABILITY; HEALTH CARE COST; HETEROZYGOTE DETECTION; HUMAN; LUNG CLEARANCE; LUNG FUNCTION; MOTHER CHILD RELATION; NEWBORN SCREENING; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PATIENT IDENTIFICATION; PHENOTYPE; PRENATAL SCREENING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SWEAT TEST; VITAMIN SUPPLEMENTATION;

BIOLOGICAL MARKERS; CYSTIC FIBROSIS; FALSE POSITIVE REACTIONS; HETEROZYGOTE DETECTION; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING; SWEAT; TRYPSINOGEN;

EID: 84861098845     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e328353489a     Document Type: Review

References (74)

1. Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep 2004;53(RR-13):1-36.
2. de Monestrol I, Brucefors AB, Sjoberg B, Hjelte L. Parental support for newborn screening for cystic fibrosis. Acta Paediatr 2011;100:209-215.
3. Crossley JR, Smith PA, Edgar BW, et al. Neonatal screening for cystic fibrosis, using immunoreactive trypsin assay in dried blood spots. Clin Chim Acta 1981;113:111-121.
4. Hale JE, Parad RB, Dorkin HL, et al. Cystic fibrosis newborn screening: using experience to optimize the screening algorithm. J Inherit Metab Dis 2010;33(Suppl 2):S255-S261.
5. Lindau-Shepard BA, Pass KA. Newborn screening for cystic fibrosis by use of a multiplex immunoassay. Clin Chem 2010;56:445-450.
6. Sommerburg O, Lindner M, Muckenthaler M, et al. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population. J Inherit Metab Dis 2010;33(Suppl 2):S263-S271.
7. Sarles J, Barthellemy S, Ferec C, et al. Blood concentrations of pancreatitis associated protein in neonates: relevance to neonatal screening for cystic fibrosis. Arch Dis Child Fetal Neonatal Ed 1999;80:F118-F122.
8. Oosterveld MJ, Schilperoort JV, Lilien MR, Arets HG. Positive neonatal screening for cystic fibrosis in neonates with renal failure. Thorax 2010;65:652-653.
9. Sontag MK, Wright D, Beebe J, et al. A new cystic fibrosis newborn screening algorithm: IRT/IRT1 upward arrow/DNA. J Pediatr 2009;155:618-622.
10. Newborn screening for cystic fibrosis; Approved guideline, Vol. 31. Wayne, PA: Clinical and Laboratory Standards Institute; 2011. This manual represents the most comprehensive information available on CF newborn screening, including program design, algorithms, and all supporting aspects from selection of mutation analysis to sweat testing and psychological support.
11. Castellani C, Massie J. Emerging issues in cystic fibrosis newborn screening. Curr Opin Pulm Med 2010;16:584-590. Excellent review of issues pertaining to choice of algorithm.
12. Groose MK, Reynolds R, Li Z, Farrell PM. Opportunities for quality improvement in cystic fibrosis newborn screening. J Cyst Fibros 2010;9:284-287.
13. Earley MC, Laxova A, Farrell PM, et al. Implementation of the first worldwide quality assurance program for cystic fibrosis multiple mutation detection in population-based screening. Clin Chim Acta 2011;412:1376-1381.
14. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-S14.
15. Nelson MR, Adamski CR, Tluczek A. Clinical practices for intermediate sweat tests following abnormal cystic fibrosis newborn screens. J Cyst Fibros 2011;10:460-465.
16. Kleyn M, Korzeniewski S, Grigorescu V, et al. Predictors of insufficient sweat production during confirmatory testing for cystic fibrosis. Pediatr Pulmonol 2011;46:23-30.
17. Legrys VA, McColley SA, Li Z, Farrell PM. The need for quality improvement in sweat testing infants after newborn screening for cystic fibrosis. J Pediatr 2010;157:1035-1037. Important discussion of issues related to sweat testing in infants.
18. Sermet-Gaudelus I, Girodon E, Roussel D, et al. Measurement of nasal potential difference in young children with an equivocal sweat test following newborn screening for cystic fibrosis. Thorax 2010;65:539-544.
19. Sands D, Oltarzewski M, Nowakowska A, Zybert K. Bilateral sweat tests with two different methods as a part of cystic fibrosis newborn screening (CF NBS) protocol and additional quality control. Folia Histochem Cytobiol 2010;48:358-365.
20. Kirk JM. A continuing role for sweat testing in an era of newborn screening for cystic fibrosis. Clin Biochem 2011;44:487-488.
21. Sermet-Gaudelus I, Girodon E, Sands D, et al. Clinical phenotype and genotype of children with borderline sweat test and abnormal nasal epithelial chloride transport. Am J Respir Crit Care Med 2010;182:929-936.
22. Lilley M, Christian S, Hume S, et al. Newborn screening for cystic fibrosis in Alberta: two years of experience. Paediatr Child Health 2010;15:590-594.
23. Ivady G, Madar L, Nagy B, et al. Distribution of CFTR mutations in Eastern Hungarians: relevance to genetic testing and to the introduction of newborn screening for cystic fibrosis. J Cyst Fibros 2011;10:217-220.
24. Makukh H, Krenkova P, Tyrkus M, et al. A high frequency of the Cystic Fibrosis 2184insA mutation in Western Ukraine: genotype-phenotype correlations, relevance for newborn screening and genetic testing. J Cyst Fibros 2010;9:371-375.
25. Loukas YL, Soumelas GS, Dotsikas Y, et al. Expanded newborn screening in Greece: 30 months of experience. J Inherit Metab Dis 2010. [Epub ahead of print]
26. Tluczek A, Orland KM, Cavanagh L. Psychosocial consequences of falsepositive newborn screens for cystic fibrosis. Qual Health Res 2011;21:174-186. Excellent study of the impact of false-positive newborn screening.
27. Tluczek A, McKechnie AC, Brown RL. Factors associated with parental perception of child vulnerability 12 months after abnormal newborn screening results. Res Nurs Health 2011;34:389-400. Important study concerning the vulnerable child syndrome.
28. Beucher J, Leray E, Deneuville E, et al. Psychological effects of false-positive results in cystic fibrosis newborn screening: a two-year follow-up. J Pediatr 2010;156:771-776;776.e1.
29. Dillard JP, Shen L, Robinson JD, Farrell PM. Parental information seeking following a positive newborn screening for cystic fibrosis. J Health Commun 2011;15:880-894.
30. Stark AP, Lang CW, Ross LF. A pilot study to evaluate knowledge and attitudes of Illinois pediatricians toward newborn screening for sickle cell disease and cystic fibrosis. Am J Perinatol 2011;28:169-176.
31. Collaco JM, Panny SR, Hamosh A, Mogayzel PJ Jr. False negative cystic fibrosis newborn screen. Clin Pediatr (Phila) 2010;49:214-216.
32. Dunn CT, Skrypek MM, Powers AL, Laguna TA. The need for vigilance: the case of a false-negative newborn screen for cystic fibrosis. Pediatrics 2011;128:e446-e449.
33. Tluczek A, Zaleski C, Stachiw-Hietpas D, et al. A tailored approach to familycentered genetic counseling for cystic fibrosis newborn screening: the Wisconsin model. J Genet Couns 2011;20:115-128.
34. Culling B, Ogle R. Genetic counselling issues in cystic fibrosis. Paediatr Respir Rev 2010;11:75-79.
35. Cavanagh L, Compton CJ, Tluczek A, et al. Long-term evaluation of genetic counseling following false-positive newborn screen for cystic fibrosis. J Genet Couns 2010;19:199-210.
36. Lang CW, McColley SA, Lester LA, Ross LF. Parental understanding of newborn screening for cystic fibrosis after a negative sweat-test. Pediatrics 2011;127:276-283.
37. La Pean A, Collins JL, Christopher SA, et al. A qualitative secondary evaluation of statewide follow-up interviews for abnormal newborn screening results for cystic fibrosis and sickle cell hemoglobinopathy. Genet Med 2011. [Epub ahead of print]
38. Sanders DB, Lai HJ, Rock MJ, Farrell PM. Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies. J Cyst Fibros 2012;11:150-153.
39. Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997;337:963-969.
40. Maclean JE, Solomon M, Corey M, Selvadurai H. Cystic fibrosis newborn screening does not delay the identification of cystic fibrosis in children with negative results. J Cyst Fibros 2011;10:333-337.
41. Mehta A. The how (and why) of disease registers. Early Hum Dev 2010;86:723-728.
42. Strom CM, Redman JB, Peng M. The dangers of including nonclassical cystic fibrosis variants in population-based screening panels: p. L997F, further genotype/phenotype correlation data. Genet Med 2011;13:1042-1044.
43. Burgel PR, Fajac I, Hubert D, et al. Nonclassic cystic fibrosis associated with D1152H CFTR mutation. Clin Genet 2010;77:355-364.
44. Baker MW, Groose M, Hoffman G, et al. Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening. J Cyst Fibros 2011;10:278-281.
45. Korzeniewski SJ, Young WI, Hawkins HC, et al. Variation in immunoreactive trypsinogen concentrations among Michigan newborns and implications for cystic fibrosis newborn screening. Pediatr Pulmonol 2011;46:125-130.
46. Thauvin-Robinet C, Munck A, Huet F, et al. The very low penetrance of cystic fibrosis for the R117H mutation: a reappraisal for genetic counselling and newborn screening. J Med Genet 2009;46:752-758.
47. Massie RJ, Poplawski N, Wilcken B, et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. Eur Respir J 2001;17:1195-1200.
48. Ren CL, Desai H, Platt M, Dixon M. Clinical outcomes in infants with cystic fibrosis transmembrane conductance regulator (CFTR) related metabolic syndrome. Pediatr Pulmonol 2011;46:1079-1084. First study of longitudinal evaluation in patients with CRMS. Results indicate a variable outcome.
49. Borowitz D, Parad RB, Sharp JK, et al. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr 2009;155(6 Suppl):S106-S116.
50. Salvatore D, Buzzetti R, Baldo E, et al. An overview of international literature from cystic fibrosis registries 2. Neonatal screening and nutrition/growth. J Cyst Fibros 2010;9:75-83.
51. Tluczek A, Becker T, Laxova A, et al. Relationships among health-related quality of life, pulmonary health, and newborn screening for cystic fibrosis. Chest 2011;140:170-177.
52. Rosenfeld M, Emerson J, McNamara S, et al. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol 2010;45:934-944.
53. Accurso FJ, Sontag MK, Wagener JS. Complications associated with symptomatic diagnosis in infants with cystic fibrosis. J Pediatr 2005;147(3 Suppl):S37-S41.
54. Dijk FN, McKay K, Barzi F, et al. Improved survival in cystic fibrosis patients diagnosed by newborn screening compared to a historical cohort from the same centre. Arch Dis Child 2011;96:1118-1123. Comparison of survival in children identified by newborn screening compared with historical controls.
55. Walsh AC, Rault G, Li Z, et al. Pulmonary outcome differences in U. S. and French cystic fibrosis cohorts diagnosed through newborn screening. J Cyst Fibros 2010;9:44-50. Interesting comparison of different outcomes in similar newborn screening populations.
56. Briesacher BA, Quittner AL, Fouayzi H, et al. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007. Pediatr Pulmonol 2011;46:770-776.
57. Borowitz D, Robinson KA, Rosenfeld M, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009;155(6 Suppl):S73-S93.
58. Sermet-Gaudelus I, Mayell SJ, Southern KW. Guidelines on the early management of infants diagnosed with cystic fibrosis following newborn screening. J Cyst Fibros 2010;9:323-329. European-based guidelines for managing infants with CF. Most, but not all, suggestions are similar to US-based guidelines.
59. Massie J, Curnow L, Gaffney L, et al. Declining prevalence of cystic fibrosis since the introduction of newborn screening. Arch Dis Child 2010;95:531-533. Intellectually stimulating discussion on whether newborn screening has altered the prevalence of CF.
60. McClaren BJ, Metcalfe SA, Aitken M, et al. Uptake of carrier testing in families after cystic fibrosis diagnosis through newborn screening. Eur J Hum Genet 2010;18:1084-1089.
61. Sanders DB, Li Z, Brody AS, Farrell PM. Chest computed tomography scores of severity are associated with future lung disease progression in children with cystic fibrosis. Am J Respir Crit Care Med 2011;184:816-821.
62. Pillarisetti N, Linnane B, Ranganathan S. Early bronchiectasis in cystic fibrosis detected by surveillance CT. Respirology 2010;15:1009-1011.
63. Lum S, Gustafsson P, Ljungberg H, et al. Early detection of cystic fibrosis lung disease: multiple-breath washout versus raised volume tests. Thorax 2007;62:341-347.
64. Hall GL, Logie KM, Parsons F, et al. Air trapping on chest CT is associated with worse ventilation distribution in infants with cystic fibrosis diagnosed following newborn screening. PLoS One 2011;6:e23932.
65. Khan TZ, Wagener JS, Bost T, et al. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
66. Pillarisetti N, Williamson E, Linnane B, et al. Infection, inflammation, and lung function decline in infants with cystic fibrosis. Am J Respir Crit Care Med 2011;184:75-81. Prospective study of early lung abnormalities in infants with CF detected by newborn screening. Findings of infection, inflammation, and abnormal lung function are compared at various ages in children studied longitudinally.
67. Ranganathan SC, Parsons F, Gangell C, et al. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax 2011;66:408-413. Valuable addition to the findings of early nutritional deficiency and airway inflammation.
68. Stafler P, Davies JC, Balfour-Lynn IM, et al. Bronchoscopy in cystic fibrosis infants diagnosed by newborn screening. Pediatr Pulmonol 2011;46:696-700.
69. Wainwright CE, Vidmar S, Armstrong DS, et al. Effect of bronchoalveolar lavage-directed therapy on Pseudomonas aeruginosa infection and structural lung injury in children with cystic fibrosis: a randomized trial. JAMA 2011;306:163-171. Pivotal study showing that clinical outcomes are not altered by surveillance bronchoscopy and lavage.
70. Abman SH, Ogle JW, Harbeck RJ, et al. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening. J Pediatr 1991;119:211-217.
71. Hayes D Jr, West SE, Rock MJ, et al. Pseudomonas aeruginosa in children with cystic fibrosis diagnosed through newborn screening: assessment of clinic exposures and microbial genotypes. Pediatr Pulmonol 2010;45:708-716. These results suggest that separate clinics for Pseudomonas positive and negative patients are not necessary when good infection control policies are in effect.
72. West SE, Zeng L, Lee BL, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002;287:2958-2967.
73. Hayes D Jr, Farrell PM, Li Z, West SE. Pseudomonas aeruginosa serological analysis in young children with cystic fibrosis diagnosed through newborn screening. Pediatr Pulmonol 2010;45:55-61.
74. Rogan MP, Reznikov LR, Pezzulo AA, et al. Pigs and humans with cystic fibrosis have reduced insulin-like growth factor 1 (IGF1) levels at birth. Proc Natl Acad Sci USA 2010;107:20571-20575. Important finding of abnormal growth factors in the CF pig model and correlating values in infants detected by newborn screening.